证券代码：002626 证券简称：金达威 公告编号：2025-051 厦门金达威集团股份有限公司 关于控股股东部分股份解除质押的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 厦门金达威集团股份有限公司（以下简称公司）近日收到公司控股股东厦 门金达威投资有限公司（以下简称金达威投资）将其所持有的本公司部分股票 解除质押的通知，现将有关事项公告如下： 一、 股东股份解除质押的基本情况 1. 本次解除质押基本情况 | | 是否为 控股股 东或第 | 本次解除 | 占其所 | 占公司 | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 股东名 | 一大股 | 质押股份 | 持股份 | 总股本 | 起始日 | 解除日期 | 质权人 | | 称 | 东及其 | 数量 | 比例 | 比例 | | | | | | 一致行 | （股） | | | | | | | | 动人 | | | | | | | | | | | | | | | 中信证 | | 金达威 | 是 | 14,315,000 | 6.76% ...

Group 1 - Chengjian Development received a dividend of 7.1282 million yuan from Beijing Jingcheng Jiaye Property Co., Ltd., in which it holds a 33.47% stake [1] - Shengnuo Bio expects a net profit attributable to shareholders of 77.0275 million to 94.1448 million yuan for the first half of 2025, representing a year-on-year increase of 253.54% to 332.10% [1] - JKN2301 dry mixed suspension has been approved for clinical trials, targeting children with influenza [5][6] Group 2 - Jindawei obtained a patent for a method of purifying natto kinase, with a validity of twenty years [2] - CITIC Guoan plans to increase its stake in China Broadcasting Hunan Company to approximately 5.29% through a capital increase of 278 million yuan [2] - Ji Electric announced the resignation of its general manager, Niu Guojun, due to work changes [3] Group 3 - Xintian Green Energy successfully issued 1.5 billion yuan in green medium-term notes with a term of 3+N years and an interest rate of 2.05% [7] - Hengrun Co. plans to invest 1.2 billion yuan in a project to produce 2,000 sets of wind turbine gearbox components [9] - Pulaide received a government subsidy of 10 million yuan, accounting for 15.87% of its audited net profit for the last fiscal year [10] Group 4 - Boteng Co. passed the EU QP audit, receiving a compliance statement for its CDMO services [12] - Zhou Dasheng added 7 self-operated stores in May, with total investments ranging from 900,000 to 6.5 million yuan [13] - Wantai Bio initiated a Phase III clinical trial for its live attenuated varicella vaccine [15] Group 5 - Shanghai Pharmaceuticals received a drug registration certificate for Pregabalin capsules in Thailand [19] - Sanxing Medical's subsidiary is expected to win contracts worth approximately 143 million yuan from State Grid projects [21] - Jiangsu Huachen plans to issue 460 million yuan in convertible bonds [24] Group 6 - Jian Gong Repair won a soil pollution remediation project worth 32.76 million yuan [25] - Dize Pharmaceutical completed patient enrollment for a global Phase III clinical trial of its drug [26] - Del Co. received acceptance for its application to issue shares for asset acquisition and raise matching funds [27] Group 7 - Beijing Kerui won multiple power grid projects with a total value of approximately 154 million yuan [27] - Xie Chuang Data signed financing lease contracts totaling 498 million yuan with Su Yin Financial Leasing [28] - Meige Intelligent submitted an application for H-share listing on the Hong Kong Stock Exchange [29][31] Group 8 - Aikodi plans to repurchase shares worth 100 million to 200 million yuan for employee stock ownership plans [54] - Kong Kong Industrial intends to sell 80% of Tianyuan Construction to its controlling shareholder [55] - Youyou Green Energy proposed a cash dividend of 12 yuan per 10 shares, totaling 50.4 million yuan [55]

一、 股东进行股票质押的基本情况 证券代码：002626 证券简称：金达威 公告编号：2025-050 厦门金达威集团股份有限公司 关于控股股东部分股份质押的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 厦门金达威集团股份有限公司（以下简称公司）近日收到公司控股股东厦门 金达威投资有限公司（以下简称金达威投资）将其所持有的公司部分股票进行股 票质押的通知，现将有关事项公告如下： （2）公司控股股东金达威投资未来半年内到期的质押股份累计数量为 4,048.5 万股，占其所持公司股份比例为 19.12%，占公司总股本比例为 6.64%， 对应融资余额为 20,676 万元，还款来源为自筹资金；未来一年内到期的质押股 份累计数量为 10,417.5 万股（含本次质押股数），占其所持公司股份比例为 49.21%， 占公司总股本比例为 17.08%，对应融资余额为 58,428 万元，还款来源为自筹资 金。金达威投资资信情况良好，具备相应的偿付能力。 （3）公司控股股东不存在非经营性资金占用、违规担保等侵害本公司利益 的情形。 | 是否为控 | 占其 | 占公 ...

发明名称：一种纳豆激酶的提纯方法 专利号：ZL 2023 1 0123432.0 证券代码：002626 证券简称：金达威 公告编号：2025-049 厦门金达威集团股份有限公司 关于取得发明专利证书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 厦门金达威集团股份有限公司（以下简称"公司"）及子公司内蒙古金达威 药业有限公司、金达威生物技术（江苏）有限公司，近日收到国家知识产权局颁 发的 1 件发明专利证书，具体情况如下： 证书号：第 8003786 号 授权公告日：2025 年 06 月 17 日 本发明属于化合物提纯技术领域，涉及一种纳豆激酶的提纯方法。采用本发 明提供的方法不仅能够获得较高的酶蛋白收率和纯度，而且还能够降低酶活损失。 上述专利的取得不会对公司生产经营产生重大影响，但有利于公司的技术创 新，充分发挥自主知识产权优势，进一步完善知识产权保护体系，增强公司的核 心竞争力。 专利权人：内蒙古金达威药业有限公司 厦门金达威集团股份有限公司 金达威生物技术（江苏）有限公司 专利权期限：二十年 专利申请日：2023 年 02 月 16 日 董 ...

证券代码：002626 证券简称：金达威 公告编号：2025-047 厦门金达威集团股份有限公司 关于控股股东部分股份质押的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 厦门金达威集团股份有限公司（以下简称公司）近日收到公司控股股东厦门 金达威投资有限公司（以下简称金达威投资）将其所持有的公司部分股票进行股 票质押的通知，现将有关事项公告如下： | | | | | | | | 限 | 份 | 冻结 | 份 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | | | 售 | 比 | 数量 | 比 | | | | | | | | | 和 | 例 | | 例 | | | | | | | | | 冻 | | | | | | | | | | | | 结 | | | | | | | | | | | | 数 | | | | | | | | | | | | 量 | | | | | 金达 | | | | | | | | | | | | 威投 | 211,712 ...

1. 本次解除质押基本情况 | | 是否为 控股股 东或第 | 本次解除 | 占其所 | 占公司 | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 股东名 | 一大股 | 质押股份 | 持股份 | 总股本 | 起始日 | 解除日期 | 质权人 | | 称 | 东及其 | 数量 | 比例 | 比例 | | | | | | 一致行 | （股） | | | | | | | | 动人 | | | | | | | | | | | | | | | 中信证 | | 金达威 | 是 | 14,315,000 | 6.76% | 2.35% | 2022-06- | 2025-06- | 券股份 | | 投资 | | | | | 20 | 17 | 有限公 | | | | | | | | | 司 | 2. 股东股份累计质押情况 截至公告披露日，上述股东及其一致行动人所持质押股份情况如下： 证券代码：002626 证券简称：金达威 公告编号：2025-048 厦门金达威集团股份有限公司 关于控股股东部分股份解除质押的公告 本公司及董事会全体成员保证信息披露内容 ...

Group 1 - The company has approved a profit distribution plan for the fiscal year 2024, which includes a cash dividend of 4.00 RMB per 10 shares, with no bonus shares issued [1][2] - The total number of shares for the distribution is based on the company's total share capital of 609,934,771 shares as of December 31, 2024 [1][2] - The cash dividend will be distributed to all shareholders registered by the equity registration date of June 19, 2025, with the ex-dividend date set for June 20, 2025 [3][4] Group 2 - The distribution plan specifies that for Hong Kong market investors and certain foreign institutions, the cash dividend will be 3.60 RMB per 10 shares after tax [2] - The company will not withhold individual income tax for shareholders, and tax obligations will be calculated based on the holding period when shares are sold [2][3] - The company assumes all legal responsibilities for any shortfall in cash dividends due to a decrease in shares held by shareholders during the distribution application period [3]

证券代码：002626 证券简称：金达威 公告编号：2025-046 厦门金达威集团股份有限公司 2024 年年度权益分派实施公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、股东大会审议通过利润分配方案等情况 厦门金达威集团股份有限公司（以下简称"公司"）2024 年年度权益分派方 案已获 2025 年 4 月 30 日召开的 2024 年度股东大会审议通过，公司 2024 年年度 权益分派方案为：公司以截止 2024 年 12 月 31 日公司总股本 609,934,771 股为基 数，向全体股东每 10 股派发现金红利 4.00 元（含税），送红股 0 股（含税），不 以公积金转增股本，剩余未分配利润结转以后年度。该次股东大会决议公告刊登 于 2025 年 5 月 6 日的公司指定信息披露媒体《证券时报》《证券日报》和巨潮资 讯网。 本次权益分派方案披露至实施期间，公司股本总额未发生变化。若本次利润 分配方案实施前公司股本发生变动，则以实施分配方案股权登记日的总股本为基 数，按照分配比例不变的原则对分配总额进行调整。本次实施的分配方案与股东 大会 ...

发明名称：一种纳豆激酶固态发酵半连续生产工艺 专利号：ZL 2023 1 0115923.0 证券代码：002626 证券简称：金达威 公告编号：2025-045 厦门金达威集团股份有限公司 关于取得发明专利证书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 厦门金达威集团股份有限公司（以下简称"公司"）及子公司内蒙古金达威 药业有限公司、金达威生物技术（江苏）有限公司，近日收到国家知识产权局颁 发的 2 件发明专利证书，具体情况如下： 一、 一种纳豆激酶固态发酵半连续生产工艺 专利申请日：2023 年 02 月 08 日 专利权人：内蒙古金达威药业有限公司 厦门金达威集团股份有限公司 金达威生物技术（江苏）有限公司 专利权期限：二十年 证书号：第 7980285 号 授权公告日：2025 年 06 月 03 日 发明名称：一种固定化生物酶及其制备方法以及虾青素单酯的合成方法 专利号：ZL 2025 1 0132862.8 专利申请日：2025 年 02 月 06 日 专利权人：内蒙古金达威药业有限公司 金达威生物技术（江苏）有限公司 厦门金达威集团股 ...

Core Insights - The company has successfully completed a 1.5 times expansion of its coenzyme Q10 raw material production line, with new fermentation tanks successfully undergoing trial runs, maintaining a strong production and sales momentum [1] - The price of vitamins has been affected by market fluctuations, while the company's DH products are enhancing competitiveness through technological upgrades and market promotion, laying a solid foundation for future market expansion [1] - The domestic health food market is growing rapidly, benefiting the company's finished health food products, which are performing well in domestic market expansion [1] - The company does not currently produce ergot sulfur, but its U.S. health supplement brand Doctor's Best has launched an ergot sulfur product sold through cross-border e-commerce platforms in the domestic market [1] - The tariff rate for the company's coenzyme Q10, vitamins, vitamin D3, and vitamin K2 exports to the U.S. is 20%, but the company is mitigating this impact by raising sales prices or having downstream customers bear the tariff [1] - The sales proportion of vitamin products in the U.S. is small, thus the impact is limited [1] - The company plans to develop product strategies and resource integration based on market insights and opportunities, aiming to create blockbuster products that can drive market momentum [1] - The company utilizes synthetic biology as a foundational technology for the large-scale production of various raw material products, including coenzyme Q10, NMN, NDH, vitamin K2, and others, while also exploring new products like astaxanthin and algal oil EP [1] Company Overview - Shenzhen Liangdu Capital Investment Management Co., Ltd. is formed by a collaboration of seasoned investment banking professionals, underwriters, M&A experts, certified public accountants, and public fund elites, possessing strong capital market operation and resource integration capabilities [2] - The firm aims to provide comprehensive services to listed companies through a combination of investment and service, achieving mutual development goals for listed companies and investors [2] - The investment team consists of professionals with master's degrees and backgrounds in finance, law, and economics, each with over ten years of experience in investment banking or investment business, having successfully completed numerous listings, restructurings, and investment projects [2]